You are here: Industry Insights > Tonix

News List

Tonix and Kansas State University to develop mRNA vaccines for Covid-19 Pharmaceutical-Technology
January 06, 2022
The ZNP technology could offer increased stability to mRNA vaccines at various temperatures.
Tonix to develop TNX-102 SL for long Covid treatment pharmaceutical-technology
June 23, 2021
Tonix Pharmaceuticals is set to develop its TNX-102 SL as a potential therapy for Long COVID syndrome, also known as post-acute sequelae of Covid-19 (PASC).
Tonix reports positive Covid-19 vaccine efficacy results in non-human primates dosed with TNX-1800 pharmaceutical-technology
March 18, 2021
Tonix Pharmaceuticals Holding has reported preliminary positive results after vaccination of non-human primates with TNX-1800, a live modified horsepox virus vaccine for percutaneous administration that is designed to express the Spike protein of ...
Tonix to focus on precision medicine approaches for Covid-19 pharmaceutical-technology
July 20, 2020
Tonix Pharmaceuticals has signed a research collaboration and option agreement with Columbia University to explore precision medicine approaches for vaccines and therapeutics against Covid-19.
Tonix and Fujifilm Enter COVID-19 Vax Deal contractpharma
June 09, 2020
Collaboration includes development of manufacturing processes and supply of clinical trial material to support Tonix’s development of TNX-1800.
Tonix exhumes positive take on data from phase 3 flop fiercebiotech
August 22, 2018
Tonix CEO Seth Lederman (Barryfc101/CC BY-SA 4.0)
Tonix exhumes positive take on data from phase 3 flop fiercebiotech
August 22, 2018
Tonix Pharmaceuticals has dug into the data from its failed phase 3 post-traumatic stress disorder trial and emerged with a positive spin on the flop.....
Tonix plunges 68% after PTSD drug failure pharmafile
July 31, 2018
Tonix Pharmaceuticals has announced that it has terminated its Phase 3 study of Tonmya (cyclobenzaprine HCl sublingual tablets) in military-related posttraumatic stress disorder (PTSD) after the drug failed to prove adequate separation from placebo in its